Primer purpose and gene QRDR gyrA TGTCCGAGATGGCCTGAAGC CGTTAATCACTTCCGTCAG GAAATGACCCGTCGTAAAGG TACAGTCTGCTCATCAGAAAG ATGAGCGATATGGCAGAGCG TGACCGAGTTCGCTTAACAG GACCGAGCTGTTCCTTGTGG GCGTAACTGCATCGGGTTCA 470 Modiﬁed from reference 6 55 gyrB 710 AE008878 54 parC 413 6 52 6 parE 493 52 RT - PCR 16S rRNA GCGGCAGGCCTAACACAT GCAAGAGGCCCGAACGTC 59/60 182 X80681 TTTTGCAGGGCGCGGTCAGAATAC TGCGGTGCCCAGCTCAACGAT AAATCGGGCTACTCCAAGTG CTACAGGCGGTGACGGTAAT ATCCGCAGCCGTAAAATGAC TGGTTCAGCGGCAGCATATA CATTACGGCTGGGCGAGTTTACC CTGGCGGAATAGTTGGCGAATGAC CGTCATGCGGGGTATTCCAAGTG CGCGCCGCCAGTTTTAGC acrB 59 184 This study soxS 59 217 9 marA 59 180 9 rob 60 180 This study ramA 107 This study 60 Regulation acrR CAGTGGTTCCGTTTTTAGTG ACAGAATAGCGACACAGAAA CGAACAGGGCGTCGTCGCTT CTGGTTGCTAAAACGCGGCG ACGGTGGTTAGCGGATTGGC AGCGGCGGACTTGTCATAGC TTGCCGCTTCCAGTAATGCTTGTT CTTTATCTGGCGGCGCTGGTTTTC CGTGTCGATAACCTGAGCGG AAGGCAGTTCCAGCGCAAAG 992 58 40 soxRS 60 1,199 40 marORAB 58 1,329 40 ramA 60 724 NC_003197 ramR 934 60 1 Gene knockout veriﬁcation acrB 3,541 a / 2 ,107 b GGATCACACCTTATTGCCAG CGGCCTTATCAACAGTGAGC GCGGACTTGTCATAGCCAGA GCTGGATATCACCGCAACAC TACCGGCTATTCGAACTTGC CTCGCTTAACGTATGTCCTT CCGCTTCCAGTAATGCTTGT GAATCATTGATGACCGCTGC 52 15 1,037 a / 1 ,818 b marA 49 52 989a / 1 ,912 b soxS 49 50 918a / 1 ,755 b ramA 49 50 a Without cassette .

a MIC ( g / ml ) of drug : Strain TC TS AM CL 1 ( 0.19 ) 0.094 ( 0.023 ) 1 ( 0.75 ) 2 ( 0.75 ) 12 ( 3 ) 0.19 ( 0.023 ) 16 ( 1 ) 96 ( 1 ) 0.25 0.008 0.125 0.75 1.5 0.064 1.5 3 0.75 0.016 0.5 1.5 1 ( 0.19 ) 0.064 ( 0.023 ) 1 ( 1 ) 3 ( 0.5 ) 1.5 ( 0.094 ) 0.25 ( 0.032 ) 4 ( 2 ) 16 ( 0.38 ) 0.094 0.023 0.094 0.5 1 0.064 1 3 104 104 - cip 104 - cip acrB : : aph 104 - cip marA : : aph 104 - cip soxS : : aph 5408 5408 - cip 5408 - cip acrB : : aph 5408 - cip ramA : : aph RESULTS Antimicrobial susceptibility .

